Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway

AIM: Regorafenib is an oral small-molecule multi kinase inhibitor. Recently, several clinical trials have revealed that regorafenib has an anti-tumor activity in gastric cancer. However, only part of patients benefit from regorafenib, and the mechanisms of regorafenib’s anti-tumor effect need furthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiao-Lin, Xu, Qi, Tang, Lei, Sun, Li, Han, Ting, Wang, Li-Wei, Xiao, Xiu-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425213/
https://www.ncbi.nlm.nih.gov/pubmed/28489887
http://dx.doi.org/10.1371/journal.pone.0177335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425213/
https://www.ncbi.nlm.nih.gov/pubmed/28489887
http://dx.doi.org/10.1371/journal.pone.0177335

Ejemplares similares